Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AEterna Zentaris Inc. (USA) (AEZS) Making Another Monster Move Today

After more than doubling yesterday, shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) are having another big day in early trading today, up by over 56%. Yesterday’s gains came after the biopharmaceutical company announced that it had enrolled its first patient for its pivotal phase 3 study of Macrilen, a treatment for growth hormone deficiency in adults, which affects approximately 75,000 adults in the U.S, Canada, and Europe. Today, the company also announced that 11,000 post-share consolidation Series B Common Share Purchase Warrants were exercised, resulting in the issuance of 365,518 additional Common Shares. The major gains of the last two days come after AEterna Zentaris was beginning to attract more attention from the investors in our database.

The number of long hedge fund bets went up by 2 in the third quarter. AEterna Zentaris Inc. was in 4 hedge funds’ portfolios at the end of the third quarter of 2015. There were just 2 hedge funds in our database with AEterna Zentaris Inc. positions at the end of the quarter prior to that. At the end of this article we will also compare AEterna Zentaris Inc. to other stocks including EnteroMedics Inc (NASDAQ:ETRM), Biodel Inc (NASDAQ:BIOD), and Rubicon Technology, Inc. (NASDAQ:RBCN) to get a better sense of its popularity.

Follow Aeterna Zentaris Inc (NASDAQ:AEZS)
Trade (NASDAQ:AEZS) Now!

To most shareholders, hedge funds are viewed as slow, old financial tools of yesteryear. While there are more than 8,000 funds with their doors open at the moment, our experts hone in on the upper echelon of this club, around 700 funds. These investment experts orchestrate most of the hedge fund industry’s total asset base, and by tracking their inimitable investments, Insider Monkey has identified a few investment strategies that have historically defeated the market. Insider Monkey’s small-cap hedge fund strategy outpaced the S&P 500 index by 12 percentage points annually for a decade in their back tests.

Now, we’re going to take a peek at the key action encompassing AEterna Zentaris Inc. (USA) (NASDAQ:AEZS).

Hedge fund activity in AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)

At the end of the third quarter, a total of 4 of the hedge funds tracked by Insider Monkey held long positions in this stock, a 100% increase from one quarter earlier. With hedge funds’ positions undergoing their usual ebb and flow, there exists an “upper tier” of noteworthy hedge fund managers who were increasing their holdings significantly (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Renaissance Technologies holds the largest position in AEterna Zentaris Inc. (USA) (NASDAQ:AEZS). Renaissance Technologies has a $1 million position in the stock, comprising less than 0.1% of its 13F portfolio. Coming in second is Sander Gerber of Hudson Bay Capital Management, with a $0.1 million position; the fund manager has less than 0.1% of his firm’s 13F portfolio invested in the stock. Other professional money managers with similar optimism consist of Ken Griffin’s Citadel Investment Group, and John Overdeck and David Siegel’s Two Sigma Advisors.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.